IL-36 is Closely Related to Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease

References

• Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–1940. doi:10.1016/S0140-6736(17)31222-9
   PubMed Web of Science ®Google Scholar
• GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–1602. doi:10.1016/S0140-6736(16)31678-6
   PubMed Web of Science ®Google Scholar
• Lamprecht B, Soriano JB, Studnicka M, et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest. 2015;148(4):971–985. doi:10.1378/chest.14-2535
   PubMed Web of Science ®Google Scholar
• O’Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(2):180–184. doi:10.1513/pats.200508-093DO
   PubMedGoogle Scholar
• Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22(4):672–688. doi:10.1183/09031936.03.00040703
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378(9795):1015–1026. doi:10.1016/S0140-6736(11)60988-4
   PubMed Web of Science ®Google Scholar
• Ravi AK, Khurana S, Lemon J, et al. Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. Respir Res. 2014;15(1):103. doi:10.1186/s12931-014-0103-4
   PubMed Web of Science ®Google Scholar
• Martin TR, Raghu G, Maunder RJ, Springmeyer SC. The effects of chronic bronchitis and chronic air-flow obstruction on lung cell populations recovered by bronchoalveolar lavage. Am Rev Respir Dis. 1985;132(2):254–260. doi:10.1164/arrd.1985.132.2.254
   PubMedGoogle Scholar
• Hunninghake GW, Gadek JE, Kawanami O, Ferrans VJ, Crystal RG. Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol. 1979;97(1):149–206.
   PubMed Web of Science ®Google Scholar
• Dhami R, Gilks B, Xie C, Zay K, Wright JL, Churg A. Acute cigarette smoke-induced connective tissue breakdown is mediated by neutrophils and prevented by alpha1-antitrypsin. Am J Respir Cell Mol Biol. 2000;22(2):244–252. doi:10.1165/ajrcmb.22.2.3809
   PubMed Web of Science ®Google Scholar
• Lams BE, Sousa AR, Rees PJ, Lee TH. Immunopathology of the small-airway submucosa in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(5 Pt 1):1518–1523. doi:10.1164/ajrccm.158.5.9802121
   PubMed Web of Science ®Google Scholar
• Yuan ZC, Xu WD, Liu XY, Liu XY, Huang AF, Su LC. Biology of IL-36 signaling and its role in systemic inflammatory diseases. Front Immunol. 2019;10:2532. doi:10.3389/fimmu.2019.02532
   PubMed Web of Science ®Google Scholar
• Ainscough JS, Macleod T, McGonagle D, et al. Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ. Proc Natl Acad Sci U S A. 2017;114(13):E2748–E2757. doi:10.1073/pnas.1620954114
   PubMed Web of Science ®Google Scholar
• Frey S, Derer A, Messbacher ME, et al. The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis. 2013;72(9):1569–1574. doi:10.1136/annrheumdis-2012-202264
   PubMed Web of Science ®Google Scholar
• Qin X, Zhang T, Wang C, Li H, Liu M, Sun Y. IL-36α contributes to enhanced T helper 17 type responses in allergic rhinitis. Cytokine. 2020;128:154992. doi:10.1016/j.cyto.2020.154992
   PubMed Web of Science ®Google Scholar
• Yi G, Ybe JA, Saha SS, et al. Structural and functional attributes of the Interleukin-36 receptor. J Biol Chem. 2016;291(32):16597–16609. doi:10.1074/jbc.M116.723064
   PubMed Web of Science ®Google Scholar
• Queen D, Ediriweera C, Liu L. Function and regulation of IL-36 signaling in inflammatory diseases and cancer development. Front Cell Dev Biol. 2019;7:317. doi:10.3389/fcell.2019.00317
   PubMed Web of Science ®Google Scholar
• Berglöf E, Andre R, Renshaw BR, et al. IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells. J Neuroimmunol. 2003;139(1–2):36–43. doi:10.1016/S0165-5728(03)00130-9
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Taniguchi Y, Matsumoto T, et al. Knockout of the interleukin-36 receptor protects against renal ischemia-reperfusion injury by reduction of proinflammatory cytokines. Kidney Int. 2018;93(3):599–614. doi:10.1016/j.kint.2017.09.017
   PubMed Web of Science ®Google Scholar
• Murrieta-Coxca JM, Rodríguez-Martínez S, Cancino-Diaz ME, Markert UR, Favaro RR, Morales-Prieto DM. IL-36 cytokines: regulators of inflammatory responses and their emerging role in immunology of reproduction. Int J Mol Sci. 2019;20(7):1649. doi:10.3390/ijms20071649
   PubMed Web of Science ®Google Scholar
• Milora KA, Fu H, Dubaz O, Jensen LE. Unprocessed Interleukin-36α regulates psoriasis-like skin inflammation in cooperation with Interleukin-1. J Invest Dermatol. 2015;135(12):2992–3000. doi:10.1038/jid.2015.289
   PubMed Web of Science ®Google Scholar
• Blumberg H, Dinh H, Trueblood ES, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med. 2007;204(11):2603–2614. doi:10.1084/jem.20070157
   PubMed Web of Science ®Google Scholar
• Zhang J, Yin Y, Lin X, et al. IL-36 induces cytokine IL-6 and chemokine CXCL8 expression in human lung tissue cells: implications for pulmonary inflammatory responses. Cytokine. 2017;99:114–123. doi:10.1016/j.cyto.2017.08.022
   PubMed Web of Science ®Google Scholar
• Ramadas RA, Ewart SL, Medoff BD, LeVine AM. Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. Am J Respir Cell Mol Biol. 2011;44(2):134–145. doi:10.1165/rcmb.2009-0315OC
   PubMed Web of Science ®Google Scholar
• Li W, Meng X, Hao Y, Chen M, Jia Y, Gao P. Elevated sputum IL-36 levels are associated with neutrophil-related inflammation in COPD patients. Clin Respir J. 2021;15(6):648–656. doi:10.1111/crj.13338
   PubMed Web of Science ®Google Scholar
• Moermans C, Damas K, Guiot J, et al. Sputum IL-25, IL-33 and TSLP, IL-23 and IL-36 in airway obstructive diseases. Reduced levels of IL-36 in eosinophilic phenotype. Cytokine. 2021;140:155421. doi:10.1016/j.cyto.2021.155421
   PubMed Web of Science ®Google Scholar
• GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–1544. doi:10.1016/S0140-6736(16)31012-1
   PubMed Web of Science ®Google Scholar
• Eisner MD, Iribarren C, Yelin EH, et al. The impact of SHS exposure on health status and exacerbations among patients with COPD. Int J Chron Obstruct Pulmon Dis. 2009;4:169–176. doi:10.2147/COPD.S4681
   PubMedGoogle Scholar
• Peacock JL, Anderson HR, Bremner SA, et al. Outdoor air pollution and respiratory health in patients with COPD. Thorax. 2011;66(7):591–596. doi:10.1136/thx.2010.155358
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa1516385
   PubMed Web of Science ®Google Scholar
• Pascoe SJ, Lipson DA, Locantore N, et al. A Phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48(2):320–330. doi:10.1183/13993003.02165-2015
   PubMed Web of Science ®Google Scholar
• Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity. J Biol Chem. 2011;286(49):42594–42602. doi:10.1074/jbc.M111.267922
   PubMed Web of Science ®Google Scholar
• Günther S, Sundberg EJ. Molecular determinants of agonist and antagonist signaling through the IL-36 receptor. J Immunol. 2014;193(2):921–930. doi:10.4049/jimmunol.1400538
   PubMed Web of Science ®Google Scholar
• Qin X, Liu M, Zhang S, Wang C, Zhang T. The role of IL-36γ and its regulation in eosinophilic inflammation in allergic rhinitis. Cytokine. 2019;117:84–90. doi:10.1016/j.cyto.2019.02.008
   PubMed Web of Science ®Google Scholar
• Magne D, Palmer G, Barton JL, et al. The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res Ther. 2006;8(3):R80. doi:10.1186/ar1946
   PubMed Web of Science ®Google Scholar
• Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem. 2004;279(14):13677–13688. doi:10.1074/jbc.M400117200
   PubMed Web of Science ®Google Scholar
• Kovach MA, Che K, Brundin B, et al. IL-36 cytokines promote inflammation in the lungs of long-term smokers. Am J Respir Cell Mol Biol. 2021;64(2):173–182. doi:10.1165/rcmb.2020-0035OC
   PubMed Web of Science ®Google Scholar
• McCombs JE, Kolls JK. Walking down the “IL”: the newfound marriage between IL-36 and chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2021;64(2):153–154. doi:10.1165/rcmb.2020-0461ED
   PubMed Web of Science ®Google Scholar
• Bagdonas E, Raudoniute J, Bruzauskaite I, Aldonyte R. Novel aspects of pathogenesis and regeneration mechanisms in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:995–1013. doi:10.2147/COPD.S82518
   PubMed Web of Science ®Google Scholar